Clinical and biochemical aspects associated with diabetic nephropathy among type 2 diabetic males in Gaza strip

  • Abstract
  • Keywords
  • References
  • PDF
  • Abstract

    Background: Diabetic nephropathy (DN) is the leading cause of end-stage renal disease, and the published data on various aspects of the disease is rare in Gaza Strip.

    Objective: to investigate clinical and biochemical aspects associated with DN among type 2 diabetic males in Gaza Strip.

    Methods: The study comprised 150 type 2 diabetic males from Gaza Strip. Data were obtained from a questionnaire interview, patients’ records, and biochemical analysis of blood and urine samples. Statistical analysis was performed using SPSS version 23.

    Results: The prevalence of DN was 71/150 (47.3%). Duration of diabetes in patients with DN was significantly higher than in patients without DN (p<0.001). Smoking, retinopathy, cardiovascular diseases (CVD) and neuropathy were significantly more frequent among patients with DN (p<0.05). Serum glucose, urea, creatinine, cholesterol and low-density lipoprotein cholesterol (LDL-C) were significantly higher, whereas high-density lipoprotein cholesterol (HDL-C) was significantly lower in patients with DN (p<0.05). Urinary albumin and Albumin/creatinine ratio (ACR) were 10 to 13 times higher in patients with DN. Conversely, glomerular filtration rate (GFR) was significantly lower in patients with DN (137.1±35.0 versus 187.8±70.8 ml/min/1.73m2, p<0.001). ACR showed significant positive correlations with duration of diabetes (r=0.311, p<0.001), glucose (r=0.308, p<0.001), urea (r=0.474, p<0.001), creatinine (r=0.356, p<0.001), cholesterol (r=0.307, p<0.001), LDL-C (r=0.319, p<0.001) and urinary albumin (r=0.942, p<0.001), and significant negative correlation with GFR (r=-0.297, p<0.001). The predicted factors of DN were duration of diabetes, smoking, retinopathy, CVD, neuropathy, glucose, urea, creatinine, cholesterol, LDL-C and GFR. The more to fewer effective predicted variables of ACR were urinary albumin, urea, creatinine, LDL-C, duration of diabetes, glucose, cholesterol and GFR.

    Conclusion: Management of some predicted factors of DN could delay the progression of the disease.

  • Keywords

    Diabetic Nephropathy; Clinical and Biochemical Aspects; Gaza Strip.

  • References

      [1] Abbas AW, Yousif WH & Khaleel KJ (2017). Oxidant, antioxidants and some biochemical parameters in patients with type 2 diabetic nephropathy. World Journal of Pharmaceutical Research 6(1), 11-21. https://doi.10.20959/wjpr20171-7494.

      [2] Abd El-Azim SA, Hassan SF, El Deib KM & Barakat MMA (2013). Protective effect of dietary Ginger extract alone or in combination with Rosiglitazone and Glimepiride on hepatotoxicity and oxidative stress in streptozotocin-induced diabetes in rats. International Journal of Advanced Research 1(10), 256-271.

      [3] Abu-Odah H, Abed Y, El-Khateeb A, Salah M & El-Nems K (2016). End-stage renal disease in the Gaza Strip and its relationship to risk factors. Journal of US-China Medical Science 13, 24-34.

      [4] Adewolu OF & Atoe K (2015). Association between albumin creatinine ratio and e-GFR in type 2 diabetes mellitus patients in Oredo Local Government Area, Benin City, South-South Nigeria. International Journal of Tropical Disease & Health 6(3), 94-101.

      [5] American Diabetes Association (2014). Diagnosis and classification of diabetes mellitus. Diabetes Care 37 (Supplement 1), S81-S90.

      [6] Backestrom C & Hursh-Cesar G (2012). Survey Research, Pennsylvania, United States: Literary Licensing, LLC, 2012.

      [7] Bamanikar SA, Bamanikar AA & Arora A (2016). Study of serum urea and creatinine in diabetic and non-diabetic patients in a tertiary teaching hospital. The Journal of Medical Research 2(1), 12-15.

      [8] Bartels H, Bohmer M & Heierli G (1972). Serum creatinine determination without protein precipitation. Clinica Chimica Acta 37, 193-197.

      [9] Bennett K & Aditya BS (2015). An overview of diabetic nephropathy: Epidemiology, pathophysiology and treatment. Journal of Diabetes Nursing 19(2), 61-67.

      [10] Bergmeyer HU (1974). Methods of enzymatic analysis, 2nd edition, Weinheim, Verlag Chemie, New York, Academic Press.

      [11] Bhalerao SD, Somannavar M, Vernekar SS, Ravishankar R & Goudar SS (2014). Risk factors for type 2 diabetes mellitus in rural population of north karnataka: a community-based cross-sectional study. International Journal of Pharma Medicine and Biological Sciences 3(1), 1-14.

      [12] Bucolo G & David H (1973). Quantitative determination of serum triglycerides by use of enzymes. Clinical Chemistry 19, 476-482.

      [13] Burtis CA, Ashwood ER & Bruns DE (2006). Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, 4th edition, USA, Elsevier.

      [14] Fabiny DL & Ertingshausen G (1971). Automated reaction-rate method for determination of serum creatinine with the CentrifiChem. Clinical Chemistry 17, 696-700.

      [15] Friedewald WT, Levy RI & Fredrickson DS (1972). Estimation of the concentration of LDL-C in plasma without use of the preparative ultracentrifuge. Clinical Chemistry 18, 499-502.

      [16] Grove TH (1979). Effect of reagent pH on determination of HDL cholesterol by precipitation with sodium phosphotungstate-magnesium. Clinical Chemistry 25, 560-564.

      [17] Grover G, Gadpayle AK & Sabharwal A (2012). Identifying patients with diabetic nephropathy based on serum creatinine in the presence of covariates in type-2 diabetes: A retrospective study. Biomed Research India 23(4), 615-624.

      [18] Harmoinen A, Ala-Houhala I & Vuorinen P (1985). Rapid and sensitive immunoassay for albumin determination in urine. Clinica Chimica Acta 149(2-3), 269-274.

      [19] Jerums G, Panagiotopoulos S, Premaratne E, MacIsaac RJ (2009). Integrating albuminuria and GFR in the assessment of diabetic nephropathy. Nature Reviews Nephrology 5(7), 397-406.

      [20] Jose MJ, Varkey V, Chandni R, Zubaida PA & Maliekkal J (2016). The role of smoking as a modifiable risk factor in diabetic nephropathy. The Journal of the Association of Physicians of India 64, 34-38.

      [21] Kawanami D, Matoba K & Utsunomiya K (2016). Dyslipidemia in diabetic nephropathy. Renal Replacement Therapy 2, 16.

      [22] Kim SS, Kim JH & Kim IJ (2016). Current challenges in diabetic nephropathy: Early diagnosis and ways to improve outcomes. Endocrinology and Metabolism (Seoul) 31(2), 245-253.

      [23] König M & Holzhütter HG (2012). Kinetic modeling of human hepatic glucose metabolism in type 2 diabetes mellitus predicts higher risk of hypoglycemic events in rigorous insulin therapy. The Journal of Biological Chemistry 287(44), 36978-36989.

      [24] Krishnaswamy R & Lukose S (2015). Evaluation of the three methods available for the estimation of creatinine clearance. International Journal of Clinical Biochemistry and Research 2(2), 83-88.

      [25] Kumawat M, Dahiya K & Ghalaut VS (2016). Biochemical markers for the progression of diabetic nephropathy. International Journal of Advanced Research 4(3), 226-230.

      [26] Lee C & Lam KSL (2015). Biomarkers of progression in diabetic nephropathy: The past, present and future. Journal of Diabetes Investigation 6(3), 247-249.

      [27] Lim AKH (2014). Diabetic nephropathy – complications and treatment. International Journal of Nephrology and Renovascular Disease 7, 361-381.

      [28] Meiatlini F, Prencipe L, Bardelli F, Giannini G & Tarli P (1978). The 4-hydroxybenzoate/4 aminophenazone chromogenic system used in the enzymic determination of serum cholesterol. Clinical Chemistry 24, 2161-2165.

      [29] Ono T, Shikata K, Obika M, Miyatake N, Kodera R, Hirota D, Wada J, Kataoka H, Ogawa D & Makino H (2014). Factors associated with remission and/or regression of microalbuminuria in type 2 diabetes mellitus. Acta Medica Okayama 68(4), 235-241.

      [30] Ozougwu JC, Obimba KC, Belonwu CD & Unakalamba CB (2013). The pathogenesis and pathophysiology of type 1 and type 2 diabetes mellitus. Journal of Physiology and Pathophysiology 4(4), 46-57.

      [31] Palestinian Ministry of Health. Diabetic questionnaire, Diabetic clinic records, Gaza strip, Palestine, 2006.

      [32] Pálsson R & Patel UD (2014). Cardiovascular complications of diabetic kidney disease. Advances in Chronic Kidney Disease 21(3), 273-280.

      [33] Prakash J, Hota JK, Singh S & Sharma OP (2006). Clinical spectrum of chronic renal failure in the elderly: a hospital based study from eastern India. International Urology and Nephrology 38(3-4), 821-827.

      [34] Radcliffe NJ, Seah J, Clarke M, Maclsaac RJ, Jerums G & Ekinci EI (2017). Clinical predictive factors in diabetic kidney disease progression. Journal of Diabetes Investigation 8(1), 6-18.

      [35] Reutens AT (2013). Epidemiology of diabetic kidney disease. The Medical Clinics of North America 97(1): 1-18.

      [36] Ritz E & Zeng X (2011). Diabetic nephropathy - Epidemiology in Asia and the current state of treatment. Indian Journal of Nephrology 21(2), 75-84.

      [37] Rodríguez-Poncelas A, Mundet-Tudurí X, Miravet-Jiménez S, Casellas A, Barrot-De la Puente JF, Franch-Nadal J & Coll-de Tuero G (2016). Chronic kidney disease and diabetic retinopathy in patients with type 2 diabetes. PLoS One 11(2), e0149448.

      [38] Sabahelkhier MK, Awadllah MA, Idrees ASM, Mohammed AAA & Idris MA (2016). A Study of lipid profile levels of type II diabetes mellitus. Nova Journal of Medical and Biological Sciences 5(2), 1-9.

      [39] Shaikh MA, Yakta D, Baloch GH & Shaikh D (2008). The age of onset of type 2 diabetes mellitus in adult population. Annals of Pakistan Institute of Medical Sciences 4(2), 109-112.

      [40] Trinder P (1969). Determination of glucose in blood using glucose oxidase. Annals of Clinical Biochemistry 6, 24-33.

      [41] Tuttle KR, Bakris GL, Bilous RW, Chiang JL, de Boer IH, Goldstein-Fuchs J, Hirsch JB, Kalantar-Zadeh K, Narva AS, Navaneethan SD, Neumiller JJ, Patel UD, Ratner RE, Whaley-Connell AT & Molitch ME (2014). Diabetic kidney disease: a report from an ADA Consensus Conference. Diabetes Care 37(10), 2864-2883.

      [42] Vinoth M, Pinto NR, Ferreira A, Vaz F & Perni S (2016). Lipid profile of diabetic kidney disease patients in rural goa, india. Journal of Medical and Dental Science Research 3(4), 25-28.

      [43] Viswanathan V, Tilak P & Kumpatla S (2012). Risk factors associated with the development of overt nephropathy in type 2 diabetes patients: A 12 years observational study. The Indian Journal of Medical Research 136(1), 46-53.

      [44] World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia Report of a WHO/IDF Consultation. Geneva, WHO, 2006.

      [45] World Health Organization. Ten facts on obesity, 2014. Available at: (accessed 13 April, 2017).

      [46] Yassin MM, Altibi HI & El Shanti AF (2011). Clinical and biochemical features of type 2 diabetic patients in Gaza Governorate, Gaza Strip. West African Journal of Medicine 30(1), 51-56.

      [47] Zenteno-Castillo P, Muñoz-López DB, Merino-Reyes B, Vega-Sánchez A, Preciado-Puga M, González-Yebra AL & Kornhauser C (2015). Prevalence of diabetic nephropathy in type 2 diabetes mellitus in rural communities of Guanajuato, Mexico. Effect after 6 months of Telmisartan treatment. Journal of Clinical & Translational Endocrinology 2, 125-128.




Article ID: 7603
DOI: 10.14419/ijm.v5i1.7603

Copyright © 2012-2015 Science Publishing Corporation Inc. All rights reserved.